Phase II of Gefitinib (IRESSA) Administered as First-line Treatment in Patients With Non-resectable Pneumonic-type Adenocarcinoma (P-ADC)
We therefore conducted a French multicentric phase II trial (IFCT 0401) to evaluate activity
and tolerance of gefitinib (250 mg/day) administered as first line treatment in patients
with non-resectable P-ADC.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Disease control rate after 3 months of treatment
Jacques Cadranel, Pr
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)